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Thyroid hormones are essential for the maintenance of preg-
nancy, and a deficiency in maternal thyroid hormone expres-
sion has been associated with early pregnancy losses (Allan 
et al. 2000). The ligands of thyroid hormone receptors (THR) 
play a major role in trophoblast differentiation and in fetal 
neurodevelopment (Ohara et al. 2004). During the develop-
ment of the fetal central nervous system, thyroid hormones 
are involved in the migration and growth of the neuronal 
cells, the establishment of synapses, myelination and cortico-
genesis (Lopez-Espinosa et al. 2009). After the 10th week of 
gestation, the presence of high-affinity nuclear binding sites 
for the thyroid hormone triiodothyronine (T
3
) can be found in 
the fetal brain (Bernal and Pekonen 1984). During the 10th 
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Summary
Thyroid hormones are essential for the maintenance of pregnancy, and a deficiency in maternal thyroid hormones has been 
associated with early pregnancy losses. The expression of THRα1, THRβ1 and THRα2 increases with gestational age. The 
aim of this study was the investigation of the protein and mRNA-levels of THR isoforms THRα1, THRα2, THRβ1 and 
THRβ2 in normal, spontaneous and recurrent miscarriages. The identification of THR-expressing cells in the decidua was 
done with double immunofluorescence. The nuclear expression of THRα1, THRα2, THRβ1 and THRβ2 is downregulated 
at protein level in spontaneous and recurrent miscarriages in villous trophoblast tissue. In decidual tissue, we found a 
significant downregulation only for THRα1 in spontaneous miscarriages. For recurrent miscarriages, THRα1 and THRβ1 
were both significantly downregulated in decidual tissue. By applying HLA-G as a trophoblast marker, we found a significant 
co-expression only for THRβ2. The results of our study show that thyroid hormone receptors THRα1, THRα2, THRβ1 
and THRβ2 are downregulated in spontaneous and recurrent miscarriages. The majority of cells expressing the thyroid 
hormone receptors in the decidua are decidual stromal cells. (J Histochem Cytochem 63:511–523, 2015)
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and 30th weeks of pregnancy, a two- to three-fold increase in 
the concentration of thyroxine binding globulin (TBG) and a 
30% to 100% increase in total T
3
 and thyroxine (T
4
) can 
occur (Kilby et al. 1998; Fantz et al. 1999). T
3
 is mostly syn-
thesized from the pro-hormone T
4
, which originates from the 
thyroid gland and is converted into T
3
 through the iodothyro-
nine deiodinase enzymes D1 and D2 (Bianco et al. 2002). 
Thyroid hormones are involved in gluconeogenesis, lipogen-
esis, cell proliferation, apoptosis and cell immunity.
Thyroid hormones bind to specific nuclear receptors 
(THR). Two genes, THRA (NR1A1) and THRB (NR1A2), 
encode the isoforms THRα and THRβ, which code for the 
four ligand-binding thyroid receptors, THRα1, THRβ1, 
THRβ2 and THRβ3, and the four non-ligand binding recep-
tors THRα2, THRΔα1, THRΔβ2 and THRΔβ3 (Robinson-
Rechavi et al. 2001; Williams 2000). Whereas the isoforms 
THRα1, THRα2 and THRβ3 are widely expressed, the 
expression of THRβ2 is rather restricted to the hypotha-
lamic/pituitary gland (Bassett et al. 2003). The hormone T
3
 
is the high-affinity ligand of THR and thereby regulates 
gene transcription (Velasco et al. 2007). After it has bound 
to the ligand binding site, THR switches into its active form 
and recruits specific co-activators such as SRC1-3, PGC-1, 
TRAP and TRBP (Lin et al. 1997). A systematic review on 
THR function in reproductive biology was published 
recently (Pestka et al. 2013).
The expression of THRα1, THRβ1 and the non-ligand 
binding THRα2 in the nuclei of syncytiotrophoblasts (ST), 
cytotrophoblasts, and stromal cells increases with gesta-
tional age (Kilby et al. 1998). Maruo et al. (1991) demon-
strated that T
3
 enhances the production of the epidermal 
growth factor (EGF). This potent growth factor increases 
the invasiveness of cytotrophoblast cells (Bass et al. 1994) 
and stimulates the synthesis of human chorionic gonadotro-
pin (hCG) and human placental lactogen by trophoblast 
cells (Barber et al. 2005). T
3
 and EGF act synergistically in 
regulating trophoblast differentiation and proliferation 
(Barber et al. 2005). It has been further shown that T
3
 is able 
to reduce apoptosis of extravillous trophoblasts (EVTs) 
(Laoag-Fernandez et al. 2004). Hence, due to the inhibition 
of apoptosis in EVTs, T
3
 may be able to promote EVT inva-
sion to the decidua (Bass et al. 1994).
The hypothalamic–pituitary–thyroid axis (HPT) and the 
hypothalamic–pituitary–ovarian axis (HPO) seem to be phys-
iologically related. It is suggested that thyroid hormone recep-
tors located in the ovaries regulate reproductive function, and 
that estrogens influence the HPT axis as well. Thyroid disor-
ders can lead to bleeding irregularities. Hyperthyroidism can 
lead to oligomenorrhea or even to anovulatory cycles. 
Hypothyroidism can result in polymenorrhea. Even if thyroid 
hormone production is compensated, ovarian function is still 
affected (Doufas and Mastorakos 2000).
A two-fold increase in miscarriage and stillbirth rates can 
result from untreated hypothyroidism (Barber et al. 2005). 
Hyperthyroidism and autoimmunity can also have severe 
effects on pregnancy outcome. Thus, the maintenance of an 
euthyroid state is crucial during pregnancy and necessary for 
the prevention of disturbed placentation syndromes such as 
preeclampsia and intrauterine growth restriction (IUGR) 
(Barber et al. 2005). IUGR can cause perinatal and neonatal 
mortality, physical handicaps in low-birth weight babies, and 
neurodevelopmental delays in toddlers (Gaffney et al. 1994). 
Kilby et al. (1998) demonstrated that a reduction in the con-




 occurs in the serum of fetuses 
affected by IUGR. They compared IUGR placental samples 
with normal pregnancy samples and found that the immunos-
taining of THRα1, THRα2 and THRβ1 was greater in IUGR 
placental samples. However, RT-PCR results showed no dif-
ference in the expression of the messenger RNA of THR 
between IUGR and normal pregnancy samples. The upregu-
lation of THR proteins in IUGR is possibly a consequence of 
the reduction in thyroid hormones in order to maintain euthy-
roidism in the tissue, with the aim of preventing poor long-
term fetal outcomes (Kilby et al. 1998).
Based on this data, the aim of the current study was to 
systematically investigate the protein and mRNA-level 
THR isoforms THRα1, THRα2, THRβ1 and THRβ2 in 
normal, spontaneous and recurrent miscarriages. In addi-




This study was approved by the Ethical Committee of the 
Medical School, Ludwig-Maximilian-University of 
Munich. Informed consent was obtained from each patient. 
All data has been encoded.
Samples from elective terminations of pregnancies (ETP, 
22 cases) were provided from private practice clinics in 
Munich, Germany. Maternal and gestational age-matched tis-
sues samples from spontaneous miscarriages (SM, 13 cases) 
and recurrent miscarriage (RM, 10 cases) were additionally 
collected from the archives of the Department of Obstetrics 
and Gynaecology-Innenstadt, Munich, Germany. Recurrent 
miscarriage is defined as ≥3 miscarriages. The mean ages of 
the women for each group were as follows: SM, 33.8 ± 4.4 
years; RM, 34.8 ± 5.8 years; and ETP, 29.7 ± 6.0 years 
(p>0.05). The mean gestational age for the SM group was 9.6 
± 1.5 weeks; for RM group, 9.6 ± 2.2 weeks, and for the ETP 
group, 8.3 ± 1.8 weeks (p>0.05). A complete list of placentas 
obtained from different weeks is presented in Table 1. 
Samples were obtained by dilatation and evacuation without 
any prior pharmaceutical induction. In cases of spontaneous 
and recurrent miscarriages, evacuation was performed within 
the first 24 hr after diagnosis. All women included in the 
study had no medical or family history. Hypothyroidism as 
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well as hyperthyroidism were excluded in all women. History 
taking was systematic, aiming to exclude—apart from com-
mon disorders—the possible implication of clotting disorders 
and autoimmune diseases, already known as aggravating fac-
tors for increased risk for miscarriages. In all samples, analy-
sis of chromosomal abnormalities was performed. This study 
was performed using PowerPlex 16HS multiple PCR system, 
which detects 16 STR loci, with the limitation of this method 
in picking up chromosomal abnormalities at base pair level. 
Analysis was performed for all samples as well as controls. 
DNA extraction and profiling was performed via the follow-
ing steps: From placental tissue, DNA was isolated with the 
help of Bio Robot EZ1 (Qiagen, Valencia, CA) as described 
by Anslinger et al. (2005). The extracted DNA was eluted in 
50 µl double-distilled water and quantified twice with the 
Quantifiler Human DNA Quantification Kit (Thermo Fisher 
Scientific; Waltham, MA) according to the manufacturer’s 
protocol. The arithmetic mean values were calculated. For 
DNA profiling the PowerPlex® 16HS multiplex PCR system 
(Promega; Fitchburg, WI) was used, with a total reaction vol-
ume of 25 µl, applying a 32-cycle program. For each step, 
300 pg DNA was added. The PCR products were analyzed 
via the ABI PRISM 3130XL capillary electrophoresis system 
(Thermo Fisher) and the results were generated with the 
GeneScan® Analysis Software and the ABI Prism® 
GenoTyper Software version 3.7 (Thermo Fischer Scientific) 
(Anslinger et al. 2005). Additionally, in all samples, microbi-
ology analysis excluded possible intra-uterine infection. All 
women had a normal first trimester vaginal swab. Following 
evacuation, specimens from ETP, RM and SM groups were 
immediately immersed in formalin and embedded in paraffin 
or snap-frozen and sectioned with a cryostat.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections (3 µm) were 
deparaffinized in xylol, rehydrated in a descending ethanol 
gradient, and subjected to epitope retrieval in a pressure 
cooker using sodium citrate buffer (pH 6.0). After returning 





in methanol (20 min) for endogenous peroxidase activity. 
Non-specific binding of the primary antibodies was blocked 
using the appropriate blocking solution. Sections were then 
incubated with primary antibodies; the salient features of 
the antibodies used are presented in Table 2. Reactivity was 
detected by using the Vectastain Elite ABC-Kit (Vector 
Laboratories, Burlingame, CA) according to the manufac-
turer’s protocol. Substrate and chromogen (3,3’-diamino-
benzidine DAB; Dako, Glostrup, Denmark) were finally 
added to the slides, which were then counterstained with 
Mayer’s acidic hematoxylin and covered. Colon (THRα1), 
term placenta (THRα2) and breast cancer tissue (THRβ1, 
THRβ2) were used for positive control staining (Fig. 1). 
Replacement of the primary antibody with mouse or rabbit 
IgG served as negative controls (Fig. 1).
The sections were examined by two independent observ-
ers using a Leitz Diaplan microscope (Leitz, Wetzlar, 
Germany). Per slide, ten fields were examined using a semi-
quantitative immunoreactive score (IRS) (Remmele and 
Stegner 1987). IRS examines the intensity and distribution 
of antigen expression and is calculated by multiplying the 
percentage of positively stained cells (0: no staining; 1: 
<10% of the cells; 2: 11% to 50%; 3: 51% to 80%, 4: >80%) 
with the intensity of staining of the cells (0: none; 1: weak; 
2: moderate; 3: strong).
Identification of THR-expressing Cells in the 
Decidua with Double Immunofluorescence
Double immunofluorescence staining was performed in 
order to identify the cells expressing nuclear receptors 
THRα1, THRα2, THRβ1 and THRβ2 in the decidua. 
Double immunofluorescence staining was carried out on 
placentas from healthy pregnancies. The sections were 
deparaffinized in xylol for 20 min and, after washing in 
ethanol, were incubated in ethanol/methanol for a further 20 
min. Next, the slides were rehydrated in an alcohol gradient 
and then placed in a pressure cooker with sodium citrate 
(pH 6.0). The slides were then washed in PBS and blocked 
with Ultra V blocking solution (Lab Vision, Thermo 
Scientific) for 15 min. The slides were then incubated with 
polyclonal anti-THRα/β rabbit IgG (Table 2) for 1 hr. After 
that, the slides were incubated with monoclonal anti-HLA-
G antibody. Sections were then incubated with Cy3-labeled 
goat-anti-rabbit IgG antibody, diluted 1:500, and Cy2-
labeled goat-anti-mouse IgG antibody, diluted 1:100 
(Dianova; Hamburg, Germany). Next, the slides were 
embedded in DAPI containing mounting buffer (Vector 
Laboratories). The slides were then analyzed with a fluores-
cence Axioskop photomicroscope (Zeiss; Oberkochen, 
Germany) and pictures were taken with a digital Axiocam 
camera system (Zeiss).
Table 1. Number of Placentas from Different Entities and 







 5 1 0 0
 6 3 0 0
 7 2 0 2
 8 8 4 2
 9 3 4 1
10 0 2 1
11 5 1 2
12 0 2 1
13 0 0 1
 n=22 n=13 n=10
514 Ziegelmüller et al. 
Evaluation of THRA and THRB Expression with 
Real Time RT-PCR (TaqMan)
RNA Extraction from Placental Tissue. Total RNA was extracted 
from the placental tissues of 13 women with spontaneous 
miscarriage, 9 women with recurrent miscarriage and 15 nor-
mal controls. The RNA was extracted from both trophoblast 
(fetal cells) and decidua (maternal cells). The RNeasy Lipid 
Tissue Mini Kit (Qiagen) was used according to the manu-
facturer’s protocol.
Table 2. Salient Features of the Primary Antibodies Used for Immunohistochemistry and Double Immunofluorescence. 




1:200 in PBS; 1 hr at room 
temperature







1:1000 in PBS; 1 hr at room 
temperature
Reagent 1 (Polymer kit) 5 min
THRalpha2
Mouse IgG1
(AbD Serotec, Raleigh, NC)
1:1000 in PBS; 1 hr at room 
temperature
Reagent 1 (Polymer kit) 5 min
THRbeta1
Polyclonal (Rabbit IgG)
(Novus Biologicals; Littleton, Colorado)
1:300 in Dako VM; 1 hr at room 
temperature
Reagent 1 (Polymer kit) 5 min
THRbeta2
Polyclonal (Rabbit IgG)
(Upstate, EMD Millipore, Billerica, MA)
1:100 in Dako VM; 1 hr at room 
temperature




1:100 in Power block;
1-fold dilution
Power block 1× 
solution.
3 min.
Figure 1. Positive and negative control staining. (A) Colon tissue was used for positive control staining of THRα1 antibodies. THRα1 
expression is found specifically in the nucleus of the mucosa (epithelium and pericryptal fibroblast sheath. (B) Negative control staining 
for (A). (C) Term placental tissue was used for THRα2 positive control staining. THRα2 expression is found in the nuclei of villous 
as well as extravillous trophoblast cells. (D) Negative control staining for (C). (E) Breast cancer tissue was used for positive control 
staining of THRβ1 antibodies. THRβ1 expression is found specifically in the nucleus of cancer cells, with high intensity staining, and 
in the surrounding stroma, with lower intensity staining. (F) Negative control staining for (E). (G) Breast cancer tissue was also used 
for positive control staining of THRβ2 antibodies. THRβ2 expression is found specifically in the nucleus of the cancer cells and not in 
surrounding stroma. (H) Negative control staining for (G). Scale, 200 µm.
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Reverse Transcription. Reverse transcription (RT) was per-
formed with the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Weiterstadt, Germany), according 
to the protocol using a mastercycler gradient (Eppendorf, 
Hamburg, Germany). RT conditions were 10 min at 25°C, 2 
hr at 37°C, and 5 sec at 85°C, followed by a hold step at 4°C.
Real-Time Reverse Transcription-PCR. Optical, 96-well, microti-
ter reaction plates were covered with optical caps and Real-
Time Reverse Transcription PCRs were accomplished in a 
volume of 20 µl containing 1 µl 20× TaqMan® Gene Expres-
sion Assay (Hs00268470_m1 for THRA and Hs00230861_
m1 for THRB, both Applied Biosystems), 10 µl 2×TaqMan® 
Univeral PCR Master Mix (Applied Biosystems), 8 µl H
2
O 
(DEPC-treated DI water; Sigma-Aldrich, Taufkirchen, Ger-
many) and 1 µl template. Thermal cycling conditions were 
95°C for 20 sec, followed by 40 cycles of amplification with 
at 95°C for 3 sec and 60°C for 30 sec. The ABI PRISM 7500 
Fast (Applied Biosystems) was used for PCR assays. Quanti-
fication was carried out by the 2-ΔΔCT method using GAPDH 
(Hs99999905_m1) as a housekeeping gene.
Statistical Evaluation 
The SPSS/PC software package, version 20 (SPSS GmbH; 
Munich, Germany) was used for data collection and pro-
cessing as well as analysis of statistical data. Values with 
p<0.05 were considered statistically significant. Mann–
Whitney U test was used for the evaluation of two indepen-
dent groups. Data were analyzed using a one-way analysis 
of variance with two independent variables.
Results
Immunohistochemistry
THRalpha1. We identified a strong expression of THRα1, 
with a median IRS value of 7.5, in nuclei of villous tropho-
blasts (Fig. 2A). The nuclei of cytotrophoblasts as well as 
that of syncytiotrophoblasts stained with high intensity, 
with an abundance of cells showing this intense staining. A 
similar result was found for the decidua samples. We identi-
fied a strong expression of THRα1, with a median IRS 
value of 6, in the nuclei of decidual cells (Fig. 2B). In pla-
cental tissue samples from patients in the SM group, we 
identified a significant downregulation in THRα1 in villous 
trophoblasts (Fig. 2C, median = 0; p<0.001) and in decidual 
cells (Fig. 2D, median = 0.5; p<0.001). In placental tissue 
samples from RM patients, we also identified a significant 
downregulation inTHRα1 in villous trophoblasts (Fig. 2E, 
median = 1; p<0.001) as well as in decidual cells (Fig. 2F, 
median = 0; p<0.001). A summary of the staining results of 
villous tissue is presented in Figure 2G and a summary of 
staining results in decidual tissue is shown in Figure 2H.
THRalpha2. We identified an intense expression of THRα2, 
with a median IRS value of 9, in the nuclei of villous tropho-
blasts (Fig. 3A). An abundance of high intensity staining was 
detected for THRα2 in the nuclei of cytotrophoblasts as well 
as in syncytiotrophoblasts. THRα2 showed a median IRS 
value of 4 in terms of its expression in the nuclei of decidual 
cells (Fig. 3B). In placental tissue samples from patients in the 
SM group, we identified a significant downregulation in 
THRα2 in villous trophoblasts (Fig. 3C; median = 1; p<0.001) 
but no significant changes in decidual cells (Fig. 3D, median = 
3.5; p=0.182). In placental tissue samples from patients in the 
RM group, we also identified a significant downregulation in 
THRα2 in villous trophoblasts (Fig. 3E; median = 0; p<0.001) 
but no changes in decidual cells (Fig. 3F; median = 3.5, 
p=0.167). A summary of the staining results of the villous tis-
sues is presented in Figure 3G, and a summary of staining 
results in decidual tissues is shown in Figure 3H.
THRbeta1. THRβ1 showed a median IRS value of 4 in the 
nuclei of villous trophoblast cells (Fig. 4A), with staining 
also observed in the nuclei of cytotrophoblasts and syncy-
tiotrophoblasts. A similar result was found in the decidua. 
We identified a median IRS value of 3 for THRβ1 staining 
in the nuclei of decidual cells (Fig. 4B). In the placental tis-
sue samples from patients in the SM group, we identified no 
significant changes in THRβ1 expression in villous tropho-
blasts (Fig. 4C; median = 3.5; p=0.083) or in decidual cells 
(Fig. 4D, median = 4; p=0.962). In the placental tissue sam-
ples from patients in the RM group—in contrast to those in 
the SM group—we identified a significant downregulation 
in THRβ1 in villous trophoblasts (Fig. 4E; median = 0; 
p<0.001) and in decidual cells (Fig. 4F, median = 1.5; 
p=0.004). A summary of the staining results for the villous 
tissue is presented in Figure 4G and a summary of staining 
results for decidual tissue is shown in Figure 4H.
THRbeta2. We identified an intense expression of THRβ2, 
with a median IRS value of 6, in the nuclei of villous tropho-
blast cells (Fig. 5A). Staining was identified in the nuclei of 
both cytotrophoblasts and syncytiotrophoblasts. A similar 
result was found in the decidua. We identified THRβ2, with 
a median IRS value of 4, in the nuclei of decidual cells (Fig. 
5B). In the placental tissue of patients in the SM group, we 
identified a significant downregulation in THRβ2 in villous 
trophoblasts (Fig. 5C, median = 3; p=0.008). In decidual 
cells, no significant changes were observed (Fig. 5D, median 
= 3; p=0.139). In the placental tissue samples from patients 
in the RM group, we also identified a significant downregu-
lation in the expression of THRβ2 in villous trophoblast 
(Fig. 5E, median = 0; p=0.001). In decidual cells, again, no 
significant changes were found (Fig. 5F, median = 3; 
p=0.094). A summary of the staining results for villous tis-
sue is presented in Figure 5G and a summary of staining 
results for decidual tissue is shown in Figure 5H.
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Identification of THR-expressing Cells in the 
Decidua with Double Immunofluorescence
THRα/β + HLA-G double fluorescence staining was used 
for the identification of EVTs expressing THR. THRα1 
staining in the nuclei of decidual cells is shown in Figure 
6A. Membrane HLA-G staining of EVTs from the same 
area is shown in Figure 6B. Triple filter excitation showing 
both THRα1 and HLA-G is depicted in Figure 6C. The 
white arrows mark those cells expressing both antigens. 
The majority of decidual cells did not stain for HLA-G but 
were positive for THRα. Therefore, the identity of these 
cells is decidual stromal cells.
THRα1/2 staining in the nuclei of decidual cells is 
shown in Figure 6D. Membrane HLA-G staining of EVTs 
from the same area is shown in Figure 6E. Triple filter exci-
tation showing both THRα1/2 and HLA-G is shown in 
Figure 6F. The white arrows mark the few cells expressing 
Figure 2. THRα1 expression is found with high intensity and distribution in normal villous trophoblast cells (A) and in the decidua (B) in 
normal tissues. In samples from patients with spontaneous miscarriage and recurrent miscarriage, we found a significant downregulation 
in THRα1 in villous trophoblast cells (C, E) and in the decidua (D, F), respectively. A summary of the staining results is given in Box plot 
analysis for villous trophoblast tissue (G) and the decidua (H). The boxes represent the range between the 25th and 75th percentiles 
with a horizontal line at the median. The bars delineate the 5th and 95th percentiles. The circle indicates values that are more than 1.5 
box-lengths, and the asterisk values more than 3.0 box-lengths from the 75th percentile. Scale, 200 µm. 
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both antigens. The majority of THRα1/2-expressing cells is 
not stained for HLA-G. The identity of these cells is decid-
ual stromal cells.
THRβ1 staining in the nuclei of decidual cells is shown in 
Figure 7A. Membrane HLA-G staining of EVTs from the 
same area is shown in Figure 7B. Triple filter excitation 
showing both THRβ1 and HLA-G is shown in Figure 7C. 
THRβ1-expressing cells are not stained for HLA-G. 
Therefore, the identity of these cells is decidual stromal cell.
THRβ2 staining in the nuclei of decidual cells is shown 
in Figure 7D. Membrane HLA-G staining of EVTs from 
the same area is shown in Figure 7E. Triple filter excita-
tion showing both THRβ2 and HLA-G is shown in Figure 
7F. The white arrows mark cells expressing both antigens. 
The majority of cells stained for HLA-G are also positive 
for THRβ2. A great number of cells expressing THRβ2 do 
not express HLA-G and therefore are decidual stromal 
cell.
Figure 3. High-intensity staining and elevated distribution of THRα2 expression in normal villous trophoblast cells (A) and in the 
decidua (B). In spontaneous miscarriage samples as well as in recurrent miscarriage samples, we found a significant downregulation of 
THRα2 in villous trophoblast cells (C, E) but not in the decidua (D, F), respectively. A summary of the staining results is given in the Box 
plot analysis for villous trophoblast tissue (G) and decidua (H). The boxes represent the range between the 25th and 75th percentiles 
with a horizontal line at the median. The bars delineate the 5th and 95th percentiles. The circle indicates values that are more than 1.5 
box-lengths from the 75th percentile. Scale, 200 µm.
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Evaluation of THRA and THRB Expression with 
Real Time RT-PCR (TaqMan)
We identified the expression of THRA and THRB in all 
cases investigated. The mRNA expression of THRA was 
downregulated to a 0.14-fold expression in samples from 
the SM group and to a 0.096-fold expression in samples 
from the RM group (p=0.001, Fig. 8A). The mRNA 
expression of THRB was downregulated to a 0.28-fold 
expression in the SM group and to a 0.04-fold expression in 
the RM group (p<0.001, Fig. 8B).
A detailed matched analysis revealed no significant dif-
ferences in THR expression in the control placentas from 
the 5th to the 11th weeks of gestation. We also analyzed fetal 
gender-related THR expression but could not identify sig-
nificant differences (p>0.05) for fetal gender.
Figure 4. Median intensity and distribution of THRβ1 expression in normal villous trophoblast cells (A) and in the decidua (B). In 
spontaneous miscarriage samples, we found no significant changes in THRβ1 in villous trophoblast cells (C) or in the decidua (D) 
as compared with the control. In recurrent miscarriage samples, we identified a significant downregulation in THRβ1 in the villous 
trophoblasts (E) as well as in the decidua (F). A summary of the staining results is given in Box plot analysis for villous trophoblast tissue 
(G) and the decidua (H). The boxes represent the range between the 25th and 75th percentiles with a horizontal line at the median. The 
bars delineate the 5th and 95th percentiles. The circle indicates values that are more than 1.5 box-lengths, and the asterisk values more 
than 3.0 box-lengths from the 75th percentile. Scale, 200 µm.
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Discussion
Within this study, we investigated the nuclear expression 
of THRα1, THRα2, THRβ1 and THRβ2. We found that 
these receptors are downregulated at protein level in vil-
lous trophoblast tissue in patients who suffer from spon-
taneous and recurrent miscarriages. In decidual tissue, we 
found a significant downregulation only in THRα1 in 
spontaneous miscarriage samples, and in THRα1 and 
THRβ1 for recurrent miscarriage samples. Using double 
immunofluorescence and HLA-G as trophoblast markers 
(Proll et al. 1999), we found a significant co-expression 
for THRβ2 only with HLA-G. Therefore, decidual stro-
mal cells seem to express the majority of THRβ2. Further, 
we were able to confirm the results found at protein level 
at mRNA level. THRA and THRB are both downregu-
lated in spontaneous and recurrent miscarriage placental 
tissue.
Figure 5. THRβ2 expression is found with high intensity and distribution in normal villous trophoblast cells (A) and with median 
expression in the decidua (B). In spontaneous miscarriage as well as in recurrent miscarriage samples, we found a significant downregulation 
in THRβ2 expression in villous trophoblast cells (C, E) but no significant change in the decidua (D, F). A summary of the staining results 
is given in Box plot analysis for villous trophoblast tissue (G) and the decidua (H). The boxes represent the range between the 25th and 
75th percentiles with a horizontal line at the median. The bars delineate the 5th and 95th percentiles. The asterisk indicates values that 
are more than 3.0 box-lengths from the 75th percentile. Scale, 200 µm.
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The scientists Pierre Chambon, Ronald M. Evans and 
Elwood V. Jensen investigated the nuclear receptor 
superfamily in the past two decades and discovered that its 
members interact with each other. The retinoid-X-receptor 
Figure 6. (A) THRα1 expression (Cy3; red) shows a high distribution in normal decidua. (B) Extravillous trophoblast cells (EVTs) 
(HLA-G positive) appear green. (C) Triple filter excitation shows cells expressing both markers (as indicated by the white arrows). The 
majority of THRα1-expressing cells are not HLA-G positive. (D) THRα1/2 expression (Cy3; red) is found in the normal decidua. (E) 
EVTs (HLA-G positive) appear green. Triple filter excitation (F) shows cells expressing both marker (marked with white arrows). Only 
very few THRα2 expressing cells are HLA-G positive. Scale, 20 µm.
Figure 7. (A) THRβ1 expression (Cy3; red) is found in normal decidua. (B) Extravillous trophoblasts (EVTs) (HLA-G positive) appear 
green. (C) Triple filter excitation shows that there are no cells expressing both markers. (D) THRβ2 expression (Cy3; red) is found in 
the normal decidua. (E) EVTs (HLA-G positive) appear green. (F) Triple filter excitation shows cells expressing both markers (marked 
with white arrows). The majority of HLA--expressing cells are also THRβ2-positive. Scale, 20 µm.
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(RXR) acts as a key player of the receptor family through 
forming heterodimers with other nuclear receptors. The for-
mation of heterodimers further activates transcription 
(Kastner et al. 1995; Mangelsdorf and Evans 1995; Zhang 
and Pfahl 1993). The thyroid hormone receptor family, 
THRα and -β, are heterodimeric partners of RXR. We pre-
viously described that upregulation of apoptotic EVTs is 
found in spontaneous and recurrent miscarriage placental 
tissue (Minas et al. 2007). In addition, we have shown that 
EVTs in the placentas of miscarriages show a significantly 
higher expression of RXRα in comparison to EVTs in pla-
centas of elective terminations of healthy pregnancies 
(Pestka et al. 2011; Toth et al. 2008). Therefore, the key 
heterodimeric partner receptor of THRs is rather upregu-
lated in contrast to the THRs. A similar trend in terms of the 
downregulation of the nuclear receptor LXR has recently 
been described by our group. Expression of the liver X 
receptor (LXR) is decreased in both villous trophoblasts 
and decidual tissues of spontaneous and recurrent miscar-
riages (Knabl et al. 2013). Peroxisome proliferator-acti-
vated receptor gamma (PPARγ) expression has further been 
investigated and was shown to be increased in miscarriages 
(Pestka et al. 2011; Toth et al. 2009; Toth et al. 2007). 
Interestingly, a recent study showed that activation of 
PPARγ signaling via rosiglitazone induced a strong down-
regulation in both THRA and THRB in brown adipose tis-
sue and in rats in vivo (Festuccia et al. 2012). Based on 
these results, we may speculate that, in miscarriages, down-
regulation of THRs is mediated by activated PPARγ as well 
as RXR. Therefore, we consider that THR downregulation 
is a cause mediated by a number of different factors.
On the other hand, an impairment of the maternal thy-
roid function, such as in hypothyroidism or thyroid autoim-
mune diseases, can also have detrimental consequences to 
embryonic and fetal development and result in an increased 
risk of miscarriage. In fact, thyroid autoantibodies are 
associated with a higher rate of both spontaneous and 
recurrent miscarriages (Budenhofer et al. 2013). Thyroid 
autoimmunity leads to an increase in miscarriage rate 
(Abalovich et al. 2007; Anselmo et al. 2004; De Geyter 
et al. 2009; Poppe et al. 2008; Smallridge et al. 2005; 
Todorova et al. 2008), especially in the first trimester (De 
Geyter et al. 2009; Poppe et al. 2008). A significant corre-
lation between the presence of thyroid antibodies and 
spontaneous pregnancy loss has been confirmed by several 
studies: A two-fold increase in the miscarriage rate was 
seen in women who were thyroid antibody-positive in the 
first trimester as compared with antibody-negative women 
(Stagnaro-Green et al. 1990). A four-fold increase in the 
miscarriage rate was present in women affected by autoim-
mune thyroid disease as compared to the healthy controls 
(Glinoer et al. 1991). In addition, it has been shown that 
miscarriage in women affected by thyroid autoimmunity 
mainly occurs during the first trimester (Lejeune et al. 
1993) and patients with recurrent miscarriage (RM) showed 
rather high incidences of thyroid antibodies (Bussen and 
Steck 1995) (Reznikoff-Etievant et al. 1999). In accor-
dance with the Endocrine Society Guidelines, hypothy-
roidism in pregnant women is indicated to be treated with 
levothyroxine, even if subclinical (Gartner and Reincke 
2008; Verga et al. 2009). The benefit of levothyroxine 
replacement in pregnant women has been demonstrated by 
several studies. Levothyroxine administration reduced 
rates of miscarriage and premature delivery in thyroid anti-
body-positive women to values similar to those of controls 
with euthyroid function (Negro et al. 2006). The incidence 
of obstetric complications is decreased when euthyroidism 
can be achieved and maintained by levothyroxine treat-
ment in pregnant hypothyroid women (Glinoer 1998; Verga 
et al. 2009). However, an improvement in fertility by levo-
thyroxine administration has not yet been proven (Gartner 
and Reincke 2008). Maternal thyroid dysfunction, espe-
cially hypothyroidism and thyroid autoimmunity, does 
have a negative influence on fetal development 
Figure 8. Results of gene expression analysis with TaqMan RT-PCR. (A) THRA expression. We identified a significant downregulation 
in THRA in samples from patients with spontaneous miscarriage as well those with recurrent miscarriage. (B) We identified a significant 
downregulation in THRB in samples from patients with spontaneous miscarriage and recurrent miscarriage.
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and obstetric outcome, and thyroid autoantibodies are 
associated with a significant increase in miscarriage rates. 
However, a consistent screening routine for thyroid (dys-)
function in pregnant women does not yet exist (Vaidya 
et al. 2012).




 are essential for 
the maintenance of pregnancy and a deficiency in maternal 
thyroid hormones is associated with miscarriages. The 
results of our study show that the expression of thyroid hor-
mone receptors THRα1, THRα2, THRβ1, and THRβ2 is 
downregulated in villous trophoblasts from spontaneous 
and recurrent miscarriages. The majority of cells expressing 
the THRs in the decidua are decidual stromal cells. Only 
THRβ2 is also expressed in EVTs.
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